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13 The scope of Cell Biology and Toxicology had been
14 opened towards translational research as was discussed
15 in the editorial of the Xiandong Wang (Gu and Wang
16 2016). Translational research supports the close collab-
17 oration of different specialties ranging from basic sci-
18 ence research to clinical studies. That approach may
19 shorten the time it takes for developing new treatment
20 possibilities or schemes. To better understand the com-
21 plexity of such methodology, hereby we review an
22 exciting field, the microbiome—from a translational
23 point of view (Fig. 1Q2 ).
24 The human body harbors symbiotic, commensal and
25 pathogenic bacteria in enormous numbers. These mi-
26 crobes live in the cavities of our bodies (e.g., gut,
27 genitals, or airways) or on the surface of the human
28 body, the skin. The ensemble of the microbes in an
29 organism is referred as the normal flora. Changes in
30 the composition of the normal flora, the invasion or
31 over-proliferation of pathogenic bacteria had long been
32 associated with diseases (e.g., Helicobacter pylori
33infection of the stomach) and had been translated al-
34ready to the everyday clinical practice. Recent develop-
35ments in research technology have vastly increased our
36knowledge on the “normal flora,”Next generation high-
37throughput sequencing experiments have demonstrated
38that there are more bacterial species in the gut than it was
39known from classical microbiological cultures. These
40studies have identified numerous new bacterial species,
41among them several obligatory anaerobic strains that are
42impossible to culture. The ensemble of microbes in a
43compartment (e.g., gut or airways), identified by se-
44quencing, is referred as the microbiome or microbiota.
45Due to the abundance and variance of microbes, the
46overall size of the genomes of these organisms exceeds
47that of the human genome, extending vastly the vari-
48ability of genes in a compartment. Therefore, several
49authors consider the microbiome as an additional organ
50and recently proposed to consider the ensemble of the
51human and microbial genomes present in one human
52being the “metagenome.”
53There is an intricate bidirectional interaction between
54the host and the microbiome. The composition of the
55microbiome is governed by the behavior (e.g., hygiene),
56feeding, metabolism, and immunological characteristics
57of the host. While the microbiome influences host metab-
58olism, immune reactions, and behavior through (1) releas-
59ing its own metabolites (e.g., short chain fatty acids), (2)
60modifying themetabolites of the host (e.g., secondary bile
61acids, primary amines, metabolites of aromatic amino
62acids (e.g., Trp), lactate, pyruvate, redox-modified sex
63steroids or polyphenols), (3) metabolizing nutrients
64(e.g., dietary fibers), or (4) synthesizing vitamins and
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65 (digestive) enzymes (Donia and Fischbach 2015; Li and
66 Chiang 2014). These bioactive substances (metabolites)
67 act through various pathways that involve the modifica-
68 tion of gene expression (e.g., activation of histone
69 deacetylases and other lipid-mediated transcription fac-
70 tors) or the modulation of signal transduction in the host.
71 In disease, the composition of the microbiome com-
72 plexity (richness) often decreases or shows characteris-
73 tic changes (Le Chatelier et al. 2013). Probably the
74 oldest observation in conjunction with microbiome
75 changes was the identification of the relationship be-
76 tween the oral microbiome, oral hygiene, and cardiovas-
77 cular diseases; bad oral hygiene increases the risk for
78 cardiovascular catastrophes. In fact, there is a surpris-
79 ingly large number of diseases that are associated with
80 changes in the microbiome.
81 The gastrointestinal (GI) tract innate immune system
82 is the first layer of communication between the gut
83 microbiome and the rest of the body. The main role of
84 it is to provide a physical barrier with the possibility of a
85 two-way communication. This communication is pro-
86 moted by intestinal epithelial cells including absorptive
87 enterocytes, mucus-producing goblet cells, hormone-
88 producing enteroendocrine cells, and antimicrobial
89 peptide- and lectin-producing Paneth cells (Ignacio
90 et al. 2016). The selective permeability allows the ab-
91 sorption of both nutrients and bacterial metabolites from
92 the gut. The uptake of bacterial metabolites contribute to
93 immune responses by providing pathogen-associated
94 molecular patterns to pattern recognition receptors such
95 as toll-like receptors, nucleotide-binding domain
96 leucine-rich repeat-containing receptors, RIG-I like
97receptors, C-type lectin family receptors, and AIM-2-
98like receptors (Ignacio et al. 2016). Consequent macro-
99phage and dendritic cell activation induces cytokine
100production which in turn leads to inflammatory Th17
101or regulatory T cell activation and may ultimately result
102in T cell dependent and independent IgA class-
103switching responses ( Q4Rescigno 2010; =Q5Farache el al.
1042013; Q6Schulz et al. 2013). Through this two-way com-
105munication, the microbiome composition affects the
106severity of autoimmune diseases like inflammatory
107bowel diseases (IBLD), asthma, rheumatoid arthritis,
108and type I diabetes (Arpaia et al. 2013; Trompette
109et al. 2014). Microbiome composition seems to have
110an intricate connection with autism and neurodegenera-
111tive illnesses such as Alzheimer’s disease ( Q7Hsiao et al.
1122013; Q8Macfabe 2013). In addition, microbiome-derived
113metabolites impact the mitochondrial metabolism of the
114host and alter susceptibility to metabolic diseases in-
115cluding obesity, insulin resistance, type II diabetes, and
116gestational diabetes (Le Chatelier et al. 2013). The
117microbiome represent the tumor microenvironment for
118gastrointestinal tumors; among them, the best studied is
119the colorectal carcinoma. Characteristic microbiome
120changes are not only associated with tumorigenesis,
121tumor promotion, and the severity of the disease, but
122the actual composition of the gut microbial community
123affects the effectivity of chemotherapy too. There are
124emerging fields such as the study of the skin
125microbiome (e.g., atopy, chronic wounds) (Wolcott
126et al. 2015), the airway (respiratory) microbiome
127(Rogers et al. 2015), aging or pregnancy, and perinatal
128development (Martinez 2014; Prince et al. 2014).
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Fig. 1Q3 The bidirectional fashion of the microbiome-host interaction
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129 Importantly, due to the bidirectional fashion of the
130 microbiome-host interaction, changes in microbiome are
131 not only passive markers of disease but seems to play an
132 active role too. Therefore, it is also possible to manage
133 diseases through modifying microbiome (Holmes et al.
134 2012) that confers a strong and widespread translational
135 potential to microbiome modification strategies. The ap-
136 plication of different prebiotics or probiotics, even in the
137 form of functional foodstuffs, are long known possibilities.
138 It is also common knowledge that antibiotics modify the
139 composition of themicrobiome, generally the variability of
140 the flora reduces upon antibiotic usage. A novel method
141 that is applied for the treatment of recurrent Clostridium
142 difficile infection is called fecal transplantation (Smits et al.
143 2013). In that process, the microbiome of the diseased
144 individual is replaced by the fecal microbiome of a healthy
145 individual (usually a family member). The introduction of
146 the fresh flora enables the regrowth of the original flora.
147 On the long run, the selective addition or transplantation of
148 bacterial strains or the construction of healthy feces banks
149 may be viable approaches. Changes in microbiome, abso-
150 lute or relative abundance of a species or a group of
151 species, can be also used as a biomarker of a disease that
152 can be retrieved in a truly noninvasive fashion.
153 As discussed earlier, bacterial metabolites are rela-
154 tively unexplored and represent huge translational po-
155 tential. These metabolites may connect different micro-
156 bial compartments or between tissues distant to the
157 microbiome. The identification and assessment of bac-
158 terial metabolites may develop into a very valued field,
159 as bacterial metabolites may represent a novel class of
160 drug candidates or disease biomarkers (Donia and
161 Fischbach 2015; Li and Chiang 2014).
162 On the top of that, there are emerging fields for applied
163 and basic research that will profoundly influence our
164 understanding of the host-microbiome relations. The in-
165 volvement of the immune system needs to be better de-
166 fined and the effects of immunomodulatory drugs, im-
167 mune deficiency to microbiome and bacterial metabolome
168 composition could be also be better understood and
169 exploited. The microbiome has an indispensable role in
170 infection control, not only bacterial, but viral, retroviral
171 infections are mediated by the composition of the
172 microbiome (Kane et al. 2011) that is another feature with
173 practical applicability. Differences in microbiome compo-
174 sition brings about differences in the secreted enzyme
175 composition (e.g., gut microbiome contributes to the di-
176 gestive enzyme pool of the intestine) and biosynthetic
177 activity (a trivial example is vitamin K synthesis in the
178large intestine) that may lead to individual differences in
179nutrient digestion, drug metabolism, and many other idio-
180syncratic features. Along the same line, we should change
181our current paradigms and imagine the microbiome as a
182warehouse of bioactive metabolites. Taken together,
183microbiome studies and inventions will surely impact on
184personalized medicine and human nutrition.
185
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